Market News & Trends
PulseSight Therapeutics Announces Initiation of Clinical Plan of Transferrin Vectorized Therapy for Dry AMD/Geographic Atrophy
PulseSight Therapeutics SAS recently announced it has submitted a Clinical Trial Authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé…
Pheno Therapeutics Granted Clinical Trial Authorization for Lead Multiple Sclerosis Therapeutic Candidate
Pheno Therapeutics Limited recently announced it has received clinical trial authorization (CTA) from the UK’s MHRA (Medicines and Healthcare products Regulatory Agency) for its lead…
Kindeva Drug Delivery & Emervax Partner to Bring Game Changing Vaccine Administration to Patients
Kindeva Drug Delivery and Emervax recently announced an exclusive partnership to co-develop a game-changing solution for the administration of vaccines targeting a variety of emerging viruses. Kindeva…
Sling Therapeutics Announces Positive Topline Results From Phase 2b/3 Trial of Oral Small Molecule Linsitinib in Patients With Thyroid Eye Disease
Sling Therapeutics, Inc. recently announced topline efficacy and safety data from the Phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe…
Invivyd Announces Continued Neutralizing Activity of PEMGARDA Against Dominant SARS-CoV-2 Variant XEC
Invivyd, Inc. recently announced new in vitro neutralization data show continued neutralizing activity of PEMGARDA (pemivibart) and pipeline candidate VYD2311 against dominant SARS-CoV-2 variant XEC.…
BioDuro Opens New Solid-Phase Peptide Synthesis Scale-Up Facility
BioDuro, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), recently announced the opening of a fully-automated solid-phase peptide synthesis scale-up laboratory at its Shanghai…
Windward Bio Launches With $200-Million Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma & COPD
Windward Bio recently announced its official launch. OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200M with the co-investment…
Menarini Group & Insilico Medicine Enter Second Exclusive Global License Agreement
The Menarini Group, Stemline Therapeutics, Inc., and Insilico Medicine recently announced the companies have entered into an exclusive licensing agreement granting Stemline the global rights…
Genenta Strengthens Agreement With AGC Biologics to Boost Cell Therapy Manufacturing
Genenta Science recently announced it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and…
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody-Based Cancer Treatments From Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) recently announced Boehringer Ingelheim has exercised an option for rights to a fourth novel oncology target from an ongoing discovery collaboration. The…
Rigel Announces R289 Granted Orphan Drug Designation for MDS
Rigel Pharmaceuticals, Inc. recently announced the US FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). R289, Rigel’s potent…
Inmagene Reports Positive Topline Results of a Nondepleting Anti-OX40 Monoclonal Antibody With an Extended Half-Life for the Treatment of Atopic Dermatitis
Inmagene Biopharmaceuticals reports additional positive topline results from the Phase 2a trial of IMG-007 in patients with moderate-to-severe AD, along with the results of a…
RheumaGen Launches With $15-Million Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases
RheumaGen, Inc. recently announced the close of a $15-million Series A financing co-led by SPRIM Global Investments and William Taylor Nominees. The financing will support…
MoonLake Initiates Three New Clinical Trials & Further Expands Portfolio of Indications for the Nanobody Sonelokimab
MoonLake Immunotherapeutics recently announced patients have been screened in three new trials across three new indications to evaluate sonelokimab, an investigational Nanobody designed to treat…
LB Pharmaceuticals Announces Positive Topline Results From Phase 2 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals Inc. recently announced positive topline results from NOVA, a Phase 2 dose finding trial in adult patients with acute schizophrenia evaluating LB-102, a…
Araris Biotech AG Announces Research Collaboration & Option to License Agreement With Chugai Pharmaceutical Co.
Araris Biotech AG recently announced it has entered a Research Collaboration and Option to License Agreement (RCO) under which Araris will use its proprietary linker-conjugation…
AerWave Completes First-in-Human Study to Advance Disease-Modifying Ultrasound-Based Therapy for COPD & Asthma
AerWave Medical recently announced the successful completion of its first-in-human (FIH) feasibility study of its disease-modifying ultrasound lung denervation therapy for chronic obstructive pulmonary disease (COPD)…
Palvella Therapeutics Announces First Patients Dosed in Phase 2 Trial of QTORIN 3.9% Rapamycin Anhydrous Gel for the Treatment of Cutaneous Venous Malformations
Palvella Therapeutics, Inc. recently announced the first patients have recently been dosed in TOIVA, a multicenter, Phase 2 clinical trial designed to evaluate the safety…
Abzena Strengthens Board With Appointment of Biopharma Industry Leader
Abzena recently announced the appointment of Moncef Slaoui, PhD, to its Board of Directors. A highly accomplished leader in the biopharmaceutical industry with over 40…
Silo Pharma Awarded Patent for Groundbreaking PTSD Treatment
Silo Pharma, Inc. recently announced the US Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application 17/954,864 for Pharmacological Prophylactics Against…
